Evans John M.'s Form 4 filing
Beam Therapeutics Inc. (BEAM) · filed Aug 20, 2021
- Accession no.
- 0000899243-21-033848
- Filed
- Aug 20, 2021
- Trade date
- Aug 19, 2021
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 7 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.99M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Evans John M.CIK 0001786304 | Director, Officer (CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 19, 2021 | Common Stock | SSaleDisposed | −400 | $96.38F2 | −$38,552 | 222,600 | Indirect | |
| Aug 19, 2021 | Common Stock | SSaleDisposed | −1,000 | $97.50F3 | −$97,500 | 221,600 | Indirect | |
| Aug 19, 2021 | Common Stock | SSaleDisposed | −3,140 | $98.74F4 | −$310,043.6 | 218,460 | Indirect | |
| Aug 19, 2021 | Common Stock | SSaleDisposed | −9,704 | $99.53F5 | −$965,839.12 | 208,756 | Indirect | |
| Aug 19, 2021 | Common Stock | SSaleDisposed | −5,456 | $100.35F6 | −$547,509.6 | 203,300 | Indirect | |
| Aug 19, 2021 | Common Stock | SSaleDisposed | −300 | $101.00 | −$30,300 | 203,000 | Indirect | |
| Aug 19, 2021 | Common Stock | MOption exerciseAcquired | +12,000 | $1.03 | +$12,360 | 1,033,525 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 19, 2021 | Common Stock | MOption exerciseDisposed | −12,000 | $0.00 | $0 | 359,345 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $96.07 to $96.97, inclusive.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $97.22 to $97.85, inclusive.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $98.33 to $98.99, inclusive.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $99.01 to $99.95, inclusive.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $100.04 to $100.99, inclusive.
Referenced by the price of 1 transaction in Table I.